Who Exports Mefloquine from India — 75 Suppliers Behind a $2.4M Market
India's mefloquine export market is supplied by 75 active exporters who collectively shipped $2.4M across 265 shipments. CIPLA LIMITED leads with a 57.3% market share, followed by KALINDI OVERSEAS and YASHICA PHARMACEUTICALS PRIVATE LIMITED. The top 5 suppliers together control 69.4% of total export value, reflecting a concentrated market structure.
Top Mefloquine Exporters from India — Ranked by Export Value
CIPLA LIMITED is the leading mefloquine exporter from India, holding a 57.3% share of the $2.4M market across 265 shipments from 75 exporters. The top 5 suppliers — CIPLA LIMITED, KALINDI OVERSEAS, YASHICA PHARMACEUTICALS PRIVATE LIMITED, ARVINCARE, DEUTSCHE LABS INC. — collectively control 69.4% of total export value, indicating a moderately concentrated market. Individual shares are: CIPLA LIMITED (57.3%), KALINDI OVERSEAS (4.8%), YASHICA PHARMACEUTICALS PRIVATE LIMITED (3.4%), ARVINCARE (2.1%), DEUTSCHE LABS INC. (1.9%).
Top Mefloquine Exporters from India
Ranked by export value · 75 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | CIPLA LIMITED ARTESUNATE 100MG+MEFLOQUINE 200MG TABLET | $1.4M | 5 | 57.3% |
| 2 | KALINDI OVERSEAS YASHIMEFMEFLOQUINEHYDROCHLORIDE TABLETS IP 250 MMEFLOQUINE TABS 250MG | $116.7K | 6 | 4.8% |
| 3 | YASHICA PHARMACEUTICALS PRIVATE LIMITED YASHIMEFMEFLOQUINEHYDROCHLORIDE TABLETS IP 250 MMEFLOQUINE TABS 250MG | $83.0K | 5 | 3.4% |
| 4 | ARVINCARE | $51.1K | 1 | 2.1% |
| 5 | DEUTSCHE LABS INC. | $46.0K | 1 | 1.9% |
| 6 | 3S CORPORATION MEFLOQUINEHYDROCHLORIDE TABLETS IP 250 MYASHIMEFMEFLOQUINE TABS 250MG | $32.4K | 2 | 1.3% |
| 7 | MEDICAMEN BIOTECH LIMITED | $28.3K | 4 | 1.2% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Mefloquine exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| CIPLA LIMITED | Warning Letter issued in | Yes, as of November | Yes | Not verified | Cipla's Pithampur facility received an FDA warning letter in November 2023 for G |
TransData Nexus reviewed the regulatory standing of 1 leading Mefloquine exporters from India. 0 hold US FDA facility approvals, 1 maintain WHO-GMP certification, and 1 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Mefloquine sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is renowned for its extensive production of Active Pharmaceutical Ingredients (APIs). The city hosts over 800 pharmaceutical companies, including major players like Dr. Reddy’s Laboratories and Aurobindo Pharma. The presence of Genome Valley, India's first biotech cluster, further enhances Hyderabad's capabilities in pharmaceutical research and development. This robust infrastructure makes Hyderabad a critical hub for sourcing high-quality APIs, which are essential for the production of medications such as Mefloquine.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is a significant center for pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production, with companies like Zydus Cadila and Intas Pharmaceuticals headquartered in this region. The area's well-developed infrastructure, including ports and transportation networks, facilitates efficient manufacturing and distribution of finished pharmaceutical products. This makes the region a strategic location for sourcing formulated drugs, including Mefloquine tablets.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt in Maharashtra serves as a crucial export gateway for India's pharmaceutical industry. With 929 pharmaceutical units, Maharashtra is a leading state in pharmaceutical manufacturing. The region's proximity to major ports and international airports facilitates seamless export operations. Companies in this cluster are well-equipped to handle large-scale production and distribution, making it an ideal hub for exporting pharmaceuticals like Mefloquine to global markets.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi, located in Himachal Pradesh, is recognized as Asia's largest pharmaceutical hub, housing over 1,000 manufacturing units. The region's growth has been significantly influenced by favorable government policies, including tax incentives and infrastructural support. Baddi's strategic location and cost-effective manufacturing capabilities make it an attractive destination for pharmaceutical production, including antimalarial drugs like Mefloquine.
5Sourcing Recommendations
- Diversify Supplier Base: To mitigate risks associated with supply chain disruptions, consider sourcing Mefloquine from multiple clusters, including Hyderabad for APIs and Ahmedabad-Vadodara for formulations.
- Leverage Export Infrastructure: Utilize the Mumbai-Thane-Raigad region's advanced export facilities to ensure timely and efficient distribution of Mefloquine to international markets.
- Optimize Cost Benefits: Take advantage of the tax incentives and cost-effective manufacturing in the Baddi-Nalagarh zone to reduce production expenses without compromising quality.
- Ensure Regulatory Compliance: Engage with suppliers who adhere to international quality standards and possess certifications from recognized authorities to maintain product integrity and market credibility.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Mefloquine exporters from India
CIPLA LIMITED — Cipla eyes acquisitions, inorganic partnerships in US market
Cipla announced plans to pursue acquisitions and inorganic partnerships in the US market to strengthen its presence. - IMPACT: Potential expansion of Cipla's Mefloquine export capabilities through increased market access.
Impact: Potential expansion of Cipla's Mefloquine export capabilities through increased market access.
Common Questions — Mefloquine Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which mefloquine supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, CIPLA LIMITED leads with 11 recorded shipments worth $1.4M. KALINDI OVERSEAS (22 shipments) and YASHICA PHARMACEUTICALS PRIVATE LIMITED (8 shipments) are also established high-volume exporters.
Q How many mefloquine manufacturers are there in India?
India has 75 active mefloquine exporters with a combined export market of $2.4M across 265 shipments to 56 countries. The top 5 suppliers hold 69.4% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for mefloquine from India?
Average FOB unit price: $9.62 per unit, ranging from $0.01 to $551.15. Average shipment value: $9.2K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 75 verified Indian exporters of Mefloquine ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 265 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 56 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
265 Verified Shipments
75 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists